Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected]. Learn more

pDONR223-MAP2K1 Citations (2)

Originally described in: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.
Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, Sellers WR, Schlegel R, Wargo JA, Hahn WC, Garraway LA Nature. 2010 Nov 24. ():.
PubMed Journal

Articles Citing pDONR223-MAP2K1

Articles
Expression of Death Receptor 4 Is Positively Regulated by MEK/ERK/AP-1 Signaling and Suppressed upon MEK Inhibition. Yao W, Oh YT, Deng J, Yue P, Deng L, Huang H, Zhou W, Sun SY. J Biol Chem. 2016 Oct 7;291(41):21694-21702. Epub 2016 Aug 30. PubMed
Copper Chelation Inhibits BRAF(V600E)-Driven Melanomagenesis and Counters Resistance to BRAF(V600E) and MEK1/2 Inhibitors. Brady DC, Crowe MS, Greenberg DN, Counter CM. Cancer Res. 2017 Nov 15;77(22):6240-6252. doi: 10.1158/0008-5472.CAN-16-1190. Epub 2017 Oct 6. PubMed

If you have published an article using this material, please email us at [email protected] to have your article added to this page.